amphiregulinGenealiases: AR · AREGB · CRDGF · SDGF
Q-omics provides the consensus-scored AREG profile across patient tissues and cancer cell-line models. AREG expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, AREG is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, AREG RNA expression shows 17,793 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where AREG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AREG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AREG survival associations across molecular data types. AREG RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AREG RNA expression–survival associations across cancer types. High AREG expression shows unfavorable associations in HNSC, ACC, UVM, KIRP and OV, but favorable associations in BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for AREG RNA expression.
This table summarizes AREG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for AREG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AREG shows lower tumor expression in BLCA and LUSC and higher tumor expression in KIRC, THCA, COAD and HNSC. The KIRC box plot shows higher AREG RNA expression in tumor versus normal tissue (log2 FC = +1.495, t-test p < 0.001).
This table shows molecular features associated with AREG in patient tissues and cancer cell lines. In patient samples, AREG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, AREG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and STOMACH.
